Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Urogenital Neoplasms Pathology
share announcement

Urogenital Neoplasms Pathology

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 1380

Special Issue Editor

Dr. Carlo Introini

E-Mail Website
Guest Editor
Unit of Urology, Department of Abdominal Surgery, Galliera Hospital, 16128 Genoa, Italy
Interests: radical cystectomy; radical prostatectomy; renal surgery; laparoscopy; robotic surgery

Special Issue Information

Dear Colleagues,

Uro-oncological diseases affect a large population of middle and advanced age in both sexes. The anatomical extension of the urinary tract determines diagnostic difficulties that require ever more innovative technology. Small-caliber fiber-optic instruments and high-definition vision systems increase diagnostic accuracy. Equally, the histopathological, molecular and genetic methods of investigation allow the resolution of the differential diagnosis. The treatment of urological neoplasms relies on more comfortable techniques for the patient, such as laparoscopy and robotic surgery, which make it possible to obtain a high standard of care and functional preservation by reducing the hospitalization time. Robotic surgery, in particular, finds application in all intra-abdominal urological neoplasms, and for this reason it has expanded all over the world. Urologists who have extensive experience in these areas are invited to contribute their experiences, projects and achievements to this Special Issue.

Dr. Carlo Introini
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • urethroscopy
  • bladder cancer
  • prostate cancer
  • renal cancer
  • robotic surgery
  • laparoscopy
  • prostate biopsy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

9 pages, 257 KiB  
Article
Quantification of Gleason Pattern 4 at MRI-Guided Biopsy to Predict Adverse Pathology at Radical Prostatectomy in Intermediate-Risk Prostate Cancer Patients
by Hubert Kamecki, Łukasz Mielczarek, Stanisław Szempliński, Małgorzata Dębowska, Paweł Rajwa, Michael Baboudjian, Jakob Klemm, Juan Gómez Rivas, Elza Modzelewska, Omar Tayara, Wojciech Malewski, Przemysław Szostek, Sławomir Poletajew, Piotr Kryst, Roman Sosnowski and Łukasz Nyk
Cancers 2023, 15(22), 5462; https://doi.org/10.3390/cancers15225462 - 17 Nov 2023
Cited by 2 | Viewed by 1023
Abstract
Background: Data on Gleason pattern 4 (GP4) amount in biopsy tissue is important for prostate cancer (PC) risk assessment. We aim to investigate which GP4 quantification method predicts adverse pathology (AP) at radical prostatectomy (RP) the best in men diagnosed with intermediate-risk (IR) [...] Read more.
Background: Data on Gleason pattern 4 (GP4) amount in biopsy tissue is important for prostate cancer (PC) risk assessment. We aim to investigate which GP4 quantification method predicts adverse pathology (AP) at radical prostatectomy (RP) the best in men diagnosed with intermediate-risk (IR) PC at magnetic resonance imaging (MRI)-guided biopsy. Methods: We retrospectively included 123 patients diagnosed with IR PC (prostate-specific antigen <20 ng/mL, grade group (GG) 2 or 3, no iT3 on MRI) at MRI-guided biopsy, who underwent RP. Twelve GP4 amount-related parameters were developed, based on GP4 quantification method (absolute, relative to core, or cancer length) and site (overall, targeted, systematic biopsy, or worst specimen). Additionally, we calculated PV×GP4 (prostate volume × GP4 relative to core length in overall biopsy), aiming to represent the total GP4 volume in the prostate. The associations of GP4 with AP (GG ≥ 4, ≥pT3a, or pN1) were investigated. Results: AP was reported in 39 (31.7%) of patients. GP4 relative to cancer length was not associated with AP. Of the 12 parameters, the highest ROC AUC value was seen for GP4 relative to core length in overall biopsy (0.65). an even higher AUC value was noted for PV × GP4 (0.67), with a negative predictive value of 82.8% at the optimal threshold. Conclusions: The lack of an association of GP4 relative to cancer length with AP, contrasted with the better performance of other parameters, indicates directions for future research on PC risk stratification to accurately identify patients who may not require immediate treatment. Incorporating formulas aimed at GP4 volume assessment may lead to obtaining models with the best discrimination ability. Full article
(This article belongs to the Special Issue Urogenital Neoplasms Pathology)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop